Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: May 22, 2024 · CIK: 1581178
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, press-release
Related Tickers: EPRX
TL;DR
Eupraxia Pharma (EPRX) filed a 6-K, check the press release for news.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 22, 2024, reporting as a foreign private issuer. The filing includes Exhibit 99.1, a press release dated May 22, 2024. The company is incorporated in Canada and its principal executive offices are located in Victoria, British Columbia.
Why It Matters
This filing indicates Eupraxia Pharmaceuticals Inc. is providing updated information to the SEC, which could include significant business developments or financial updates relevant to investors.
Risk Assessment
Risk Level: low — A 6-K filing is a routine report for foreign private issuers and typically contains updates or press releases, not inherently high-risk information.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- May 22, 2024 (date) — Filing date and press release date
- Bruce Cousins (person) — Signatory for the filing
- Victoria, British Columbia, Canada (location) — Location of principal executive offices
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that is made public in their home country, filed with a stock exchange, or distributed to shareholders.
What specific document is included as part of this 6-K filing?
Exhibit 99.1, a Press Release dated May 22, 2024, is included as part of this report.
Where are Eupraxia Pharmaceuticals Inc.'s principal executive offices located?
The company's principal executive offices are located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada.
Who signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
Bruce Cousins signed the Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.
Does Eupraxia Pharmaceuticals Inc. file annual reports under Form 20-F or Form 40-F?
Eupraxia Pharmaceuticals Inc. files annual reports under Form 40-F.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.2 · Accepted 2024-05-22 07:04:30
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 16KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-000648.txt ( ) — 60KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: May 22, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer